86
Participants
Start Date
February 28, 2005
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
Lofexidine
Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
Placebo
Lofexidine Placebo
Yale University, Psychiatry, New Haven
National Institute on Drug Abuse (NIDA)
NIH
Yale University
OTHER